Abstract
Induction of apoptosis in cancer cells with chemotherapy and radiation treatment is a major strategy in cancer therapy at present. Nevertheless, innate or acquired resistance has been an obstacle for conventional clinical therapy. TNF-related apoptosis inducing ligand (TRAIL / Apo-2L) is a typical member of the TNF ligand family that induces apoptosis through activating the death receptors. In recent years, considerable attention has been focused on the potential benefits of TRAIL in cancer therapy, as the majority of cancer cells are sensitive to TRAIL-induced apoptosis, while most normal cells are TRAIL-resistant. Furthermore, the use of TRAIL in combination with chemotherapeutic agents or irradiation strengthens its apoptotic effects. In this review, we will discuss the regulation mechanism of TRAIL-induced apoptosis and the molecular basis of the synergies created by its use in combination with chemotherapeutic agents and irradiation. We also analyze in detail that TRAIL may be cytotoxic, as this is a potential obstacle to its development for being used in cancer therapy.
Keywords: trail, cancer therapy, tnf-related apoptosis inducing ligand, tnf ligand family, death receptors, trail-resistant
Current Molecular Medicine
Title: TRAIL: A Potential Agent for Cancer Therapy
Volume: 3 Issue: 8
Author(s): Juan Shi, Dexian Zheng, Kwan Man, Sheung-tat Fan and Ruian Xu
Affiliation:
Keywords: trail, cancer therapy, tnf-related apoptosis inducing ligand, tnf ligand family, death receptors, trail-resistant
Abstract: Induction of apoptosis in cancer cells with chemotherapy and radiation treatment is a major strategy in cancer therapy at present. Nevertheless, innate or acquired resistance has been an obstacle for conventional clinical therapy. TNF-related apoptosis inducing ligand (TRAIL / Apo-2L) is a typical member of the TNF ligand family that induces apoptosis through activating the death receptors. In recent years, considerable attention has been focused on the potential benefits of TRAIL in cancer therapy, as the majority of cancer cells are sensitive to TRAIL-induced apoptosis, while most normal cells are TRAIL-resistant. Furthermore, the use of TRAIL in combination with chemotherapeutic agents or irradiation strengthens its apoptotic effects. In this review, we will discuss the regulation mechanism of TRAIL-induced apoptosis and the molecular basis of the synergies created by its use in combination with chemotherapeutic agents and irradiation. We also analyze in detail that TRAIL may be cytotoxic, as this is a potential obstacle to its development for being used in cancer therapy.
Export Options
About this article
Cite this article as:
Shi Juan, Zheng Dexian, Man Kwan, Fan Sheung-tat and Xu Ruian, TRAIL: A Potential Agent for Cancer Therapy, Current Molecular Medicine 2003; 3 (8) . https://dx.doi.org/10.2174/1566524033479401
DOI https://dx.doi.org/10.2174/1566524033479401 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Baicalin Suppresses Migration, Invasion and Metastasis of Breast Cancer via p38MAPK Signaling Pathway
Anti-Cancer Agents in Medicinal Chemistry Effects of Some Metal Ions on Human Erythrocyte Glutathione Reductase:An In Vitro Study
Protein & Peptide Letters Microarrays and the Genetic Analysis of Brain Tumors
Current Genomics An Overview of Highly Optically Pure Chloramphenicol Bases: Applications and Modifications
Mini-Reviews in Medicinal Chemistry Aptamer-Mediated Cancer Gene Therapy
Current Gene Therapy New Biomarkers for Colon Cancer Diagnosis: A Review of Recent Patents
Recent Patents on Biomarkers The Effects of Sevoflurane or Remifentanil on the Stress Response to Surgical Stimulus
Current Pharmaceutical Design Statistically Designed Extraction of Herbs Using Ultrasound Waves: A Review
Current Pharmaceutical Design Stress-Activated MAP Kinase Cascades in Cellular Senescence
Current Medicinal Chemistry Tumour Reactions to Hypoxia
Current Molecular Medicine Towards a “Metabolic” Subtype of Major Depressive Disorder: Shared Pathophysiological Mechanisms May Contribute to Cognitive Dysfunction
CNS & Neurological Disorders - Drug Targets Novel Anticancer Agents and Targets: Recent Advances and Future Perspectives
Mini-Reviews in Medicinal Chemistry Repulsive Guidance Molecules (RGMs) and Their Potential Implication in Cancer as Co-receptor of BMPs
Current Signal Transduction Therapy Diffuse Correlation Spectroscopy (DCS): A Diagnostic Tool for Assessing Tissue Blood Flow in Vascular-Related Diseases and Therapies
Current Medical Imaging Roles of Natural Compounds from Medicinal Plants in Cancer Treatment: Structure and Mode of Action at Molecular Level
Medicinal Chemistry GSK-3 Inhibitors in the Regulation and Control of Colon Carcinoma
Current Drug Targets Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Prospects of Bacteriotherapy with Nanotechnology in Nanoparticledrug Conjugation Approach for Cancer Therapy
Current Medicinal Chemistry Optimization and Evaluation of Micromeritic and Release Properties of High Dose Flutamide Liquisolid Systems
Letters in Drug Design & Discovery Optical Image-Guided Cancer Therapy
Current Pharmaceutical Biotechnology